Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)59.76bn
  • Net income in CHF14.02bn
  • Incorporated1966
  • Employees101.47k
  • Location
    Roche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttp://www.roche.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ROG:SWX since
announced
Transaction
value
GenMark Diagnostics IncDeal completed15 Mar 202115 Mar 2021Deal completed17.77%1.84bn
Data delayed at least 15 minutes, as of Nov 26 2021 16:33 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Novartis AG48.40bn9.06bn179.57bn108.00k18.393.1512.523.714.014.0121.4023.450.41762.196.37457,478.707.826.4110.398.0170.6569.3918.7317.790.6482--0.375681.092.62-0.183813.022.84-5.914.69
Roche Holding AG59.76bn14.02bn313.25bn101.47k22.078.1016.105.2416.2516.2569.2444.270.71032.285.12588,922.3017.6214.8226.0722.0871.1571.3924.8020.920.910680.510.26666.01-5.113.915.9110.0313.842.36
Data as of Nov 26 2021. Currency figures normalised to Roche Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

15.35%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 202019.94m2.84%
The Vanguard Group, Inc.as of 05 Nov 202118.82m2.68%
UBS Asset Management Switzerland AGas of 03 Nov 202111.81m1.68%
BlackRock Fund Advisorsas of 04 Nov 202111.53m1.64%
Fidelity Management & Research Co. LLCas of 30 Sep 202110.58m1.51%
Credit Suisse Asset Management (Schweiz) AGas of 31 Oct 20218.79m1.25%
Massachusetts Financial Services Co.as of 31 Oct 20217.60m1.08%
Z�rcher Kantonalbank (Investment Management)as of 30 Jul 20216.90m0.98%
Flossbach von Storch AGas of 30 Sep 20216.54m0.93%
BlackRock Advisors (UK) Ltd.as of 04 Nov 20215.31m0.76%
More ▼
Data from 31 Dec 2020 - 31 Oct 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.